About this trial

GynCAT is a prospective cohort study that will be conducted on female patients with gynecologic malignancies scheduled for systemic antineoplastic treatment, aiming at development and validation of a Risk Assessment Model (RAM) for Venous Thromboembolism (VTE) in this specific population.

Eligibility criteria

Qualifiers

Female sex;

Diagnosis of gynecologic neoplasm (ovarian, tubal, uterine, cervical, vaginal, vulvar neoplasm);

Planned new line of systemic antineoplastic treatment;

Age of 18 years or older;

Disqualifiers

Pregnant or breastfeeding women;

Indication to receive therapeutic dose anticoagulant therapy (e.g., atrial fibrillation, mechanical heart valve);

Diagnosis of symptomatic VTE at the time of screening for enrollment.

Trial design

Treatments tested in this trial

  • Anticoagulant

Treatment groups

1,800 Participants
are divided into 1 treatment group

Locations

1
Agostino Gemelli University Polyclinic Foundation IRCCS00168, Rome Italy

Sponsors and collaborators

Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Lead sponsor

Fondazione Umberto Veronesi

Collaborator